Tango Therapeutics. Every tracked FinTwit mention of $TNGX, newest first. 14 mentions since the first on Jul 24, 2025. See the price chart.
June 2026 · 10 mentions
Jun 12
Adam Feuerstein ✡️ — ‘Synthetic lethality’ could trigger another round of biotech M&A $RVMD $TNGX $BMY $ERAS https://t.co/UQ7BPhLh6x↗
Jun 10
Jacob Plieth — What a week so far:
$RHHBY $NRIX deal
$JNJ buys Firefly
$GSK buys $NUVL
$PBLS $770m IPO + $100m placement
$TRLN going public by reverse merger ($900m cash)
$TNGX $600m secondary
$…↗
Jun 8
Adam Feuerstein ✡️ — Re: PRMT5. I had forgotten until just now, but when $BMY bought Mirati, the deal included a CVR worth $1B ($12/share) for Mirati’s PRMT5 inhibitor, now known as navlimetostat. It p…↗
Adam Feuerstein ✡️ — Follow up on the $TNGX data from this morning.
Cross-trial comparison caveats....
Daraxonrasib ORR results from the RASolute302 study: https://t.co/MJsD6KWPIi↗
Jacob Plieth — Some context for that 92% ORR / 90% 6mth landmark PFS in pancreatic cancer for the $TNGX vopimetostat + daraxonrasib combo:
vopimetostat monorx 25% ORR, ~90% 6mth PFS
$RVMD darax…↗
Jun 8
Adam Feuerstein ✡️ — Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate $TNGX $RVMD https://t.co/jk2fNmqb84 via @DrewQJoseph↗
Jun 8
Jacob Plieth — $TNGX hoping to bask in some reflected glory today?↗
Jun 8
Adam Feuerstein ✡️ — $TNGX pancreatic cancer data -- vopimetostat (PRMT5 inhibitor) combined with $RVMD daraxonrasib
https://t.co/wM52qrNiGy↗
February 2026 · 1 mention
Feb 26
Jacob Plieth — $RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN s…↗
October 2025 · 2 mentions
Oct 24
Jacob Plieth — @bioinvestor24 So not ORR in 8 patients, but PFS in 12 patients (excluding 12 censored)? Got it $TNGX↗
Oct 24
Jacob Plieth — I often marvel at some biotechs' inability to present data in anything like a logical fashion. Is $TNGX being deliberately confusing or is it just incompetent?↗